Despite convincing evidence for the effect of HSD3B1 (1245C) on PC progression among patients treated with ADT, the data are less consistent for patients receiving more novel anti-androgen treatment—abiraterone—a selective CYP17A1 inhibitor that reduces extra-gonadal synthesis of androgen [30,31,32,33]. The gene discussed is CYP17A1; the disease is pachyonychia congenita.